Skip to main content
logo
Fennec Pharmaceuticals Inc. (FENC)
NASDAQ: FENC · Real-Time Price · USD
5.77
-0.14 (-2.37%)
Mar 30, 2026, 4:00 PM EDT - Market closed

Fennec Pharmaceuticals Income Statement

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
FY 2025FY 2024
Period Ending
Dec '25 Dec '24
Revenue
44.6447.54
Revenue Growth (YoY)
-6.09%-
Cost of Revenue
3.763.18
Gross Profit
40.8844.35
Selling, General & Admin
46.9141.48
Research & Development
0.250.31
Total Operating Expenses
47.1641.79
Operating Income
-6.282.57
Interest Income
0.791.68
Interest Expense
-2.08-4.07
Other Non-Operating Income (Expense)
-2.06-0.25
Total Non-Operating Income (Expense)
-3.35-2.64
Pretax Income
-9.64-0.07
Provision for Income Taxes
0.110.37
Net Income
-9.74-0.44
Net Income to Common
-9.74-0.44
Shares Outstanding (Basic)
2927
Shares Outstanding (Diluted)
2927
Shares Change (YoY)
4.70%-
EPS (Basic)
-0.34-0.02
EPS (Diluted)
-0.34-0.02
Shares Outstanding
28.1227.53
Free Cash Flow
-12.4726.98
Free Cash Flow Per Share
-0.440.99
Gross Margin
91.57%93.30%
Operating Margin
-14.07%5.40%
Profit Margin
-21.82%-0.92%
FCF Margin
-27.94%56.75%
EBITDA
-6.282.57
EBIT
-6.282.57
EBIT Margin
-14.07%5.40%
Effective Tax Rate
-1.10%-514.08%
Updated Mar 24, 2026. Data Source: Fiscal.ai. Standard template. Financial Sources.
SEC Filings: 10-K · 10-Q